Neuronetics, Inc. (NASDAQ:STIM – Get Free Report) Director Glenn P. Muir bought 25,000 shares of the stock in a transaction on Thursday, September 5th. The stock was acquired at an average cost of $0.80 per share, for a total transaction of $20,000.00. Following the acquisition, the director now directly owns 289,818 shares in the company, valued at $231,854.40. The transaction was disclosed in a filing with the SEC, which is available through this link.
Neuronetics Price Performance
NASDAQ:STIM opened at $0.78 on Friday. The company has a quick ratio of 2.37, a current ratio of 2.58 and a debt-to-equity ratio of 2.38. The company has a 50-day moving average of $1.47 and a 200-day moving average of $2.58. Neuronetics, Inc. has a 52 week low of $0.66 and a 52 week high of $5.07.
Neuronetics (NASDAQ:STIM – Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.06). The business had revenue of $16.45 million for the quarter, compared to the consensus estimate of $18.76 million. Neuronetics had a negative return on equity of 109.00% and a negative net margin of 45.06%. During the same quarter in the prior year, the business earned ($0.17) EPS. As a group, research analysts forecast that Neuronetics, Inc. will post -0.87 EPS for the current fiscal year.
Institutional Trading of Neuronetics
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on the company. JMP Securities reduced their price objective on Neuronetics from $7.00 to $3.00 and set a “market outperform” rating for the company in a research report on Wednesday, August 14th. Canaccord Genuity Group decreased their price target on shares of Neuronetics from $6.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. Finally, William Blair reissued a “market perform” rating on shares of Neuronetics in a research report on Monday, August 12th.
Check Out Our Latest Research Report on STIM
About Neuronetics
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Read More
- Five stocks we like better than Neuronetics
- What is Put Option Volume?
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- What is a Low P/E Ratio and What Does it Tell Investors?
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- 3 Small Caps With Big Return Potential
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.